Vectors Research Management’s Elevance Health ELV Stock Holding History

Vectors Research Management’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-147	Closed	-$71K	–	240
2022 Q2	$71K	Hold	147	–	–	0.02%	196
2022 Q1	$72K	Sell	147 -96	-40%	-$43.9K	0.02%	198
2021 Q4	$113K	Hold	243	–	–	0.02%	197
2021 Q3	$91K	Hold	243	–	–	0.02%	201
2021 Q2	$93K	Sell	243 -18	-7%	-$6.88K	0.02%	197
2021 Q1	$94K	Hold	261	–	–	0.03%	188
2020 Q4	$84K	Buy	261 +188	+258%	+$57.7K	0.03%	171
2020 Q3	$20K	Hold	73	–	–	0.01%	245
2020 Q2	$19K	Buy	73 +70	+2,333%	+$18.7K	0.01%	242
2020 Q1	$1K	Sell	3 -8	-73%	-$2.18K	﹤0.01%	454
2019 Q4	$3K	Hold	11	–	–	﹤0.01%	465
2019 Q3	$3K	Hold	11	–	–	﹤0.01%	403
2019 Q2	$3K	Hold	11	–	–	﹤0.01%	365
2019 Q1	$3K	Hold	11	–	–	﹤0.01%	360
2018 Q4	$3K	Buy	+11	New	+$3.02K	﹤0.01%	566

Other funds holding ELV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vectors Research Management's ELV Position: Q3 2022 in Review

Vectors Research Management sold out of Elevance Health (ELV) in Q3 2022, closing a stake of 147 shares — an estimated $71K sold.

Vectors Research Management first reported a position in ELV in Q4 2018 and held it in 15 quarters. The position peaked at $113K in Q4 2021. 1,445 funds tracked by Wall St. Rank hold ELV as of Q3 2022.

Vectors Research Management reported no remaining Elevance Health position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 147 Elevance Health shares in Q3 2022, an estimated $71K.
Vectors Research Management first reported a position in Elevance Health in Q4 2018 and held it in 15 quarters.
Vectors Research Management's Elevance Health position peaked at $113K in Q4 2021.
1,445 funds tracked by Wall St. Rank held Elevance Health as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.